News ArticleGranules India Posts 20% Revenue Growth to INR 15,600 Mn and 39% Rise in PAT in Q2FY27
Company reports INR 3,376 Mn EBITDA and strengthens net cash to INR 8,280 Mn amid ongoing investment in generics and CDMO segments
Granules India Limited posted a 20% year-on-year rise in revenue to INR 15,600 million for Q2FY27, alongside a 39% increase in profit after tax to INR 1,818 million, driven by strong North American market sales and continued investment in R&D and manufacturing. The company achieved EBITDA of INR 3,376 million and maintained a net cash position of INR 8,280 million at quarter-end.
Granules India Limited
General / Other
Granules India Limited announced strong financial results for the quarter ended September 30, 2026, with revenue from operations reaching INR 15,600 million, a 20% increase year-on-year, and profit after tax rising 39% to INR 1,818 million.
Revenue growth was driven mainly by the North America market, contributing 72% of sales, while European revenue increased its share to 16%. The company’s revenue composition included 73% finished dosages, 13% active pharmaceutical ingredients, 10% pharmaceutical formulation intermediates, and 3% peptides CDMO.
EBITDA for the quarter was INR 3,376 million with a margin of 22%, and profit before tax stood at INR 2,434 million, marking a 38% increase compared to the previous year.
Granules India ended the quarter with a net cash position of INR 8,280 million, significantly improving from a net debt of INR 1,012 million in the previous quarter, supported by warrant proceeds.
The company recently underwent a US FDA audit at its Gagillapur site, which it expects to resolve through corrective actions without material impact on operations.
Management reiterated focus on complex generics and peptide CDMO and plans to invest the healthy cash reserves into research, manufacturing, and quality initiatives.
Highlights
- Q2FY27 revenue at INR 15,600 million, up 20% year-on-year
- Profit after tax rose 39% to INR 1,818 million
- EBITDA margin maintained at 22% for Q2FY27
- North America accounted for 72% of revenue; Europe increased to 16%
- Net cash position improved to INR 8,280 million from net debt of INR 1,012 million in Q1FY27
- Company filed three potential first-to-file ANDAs in the first half of FY27
Key Data Snapshot
What happened
- Granules India posted 20% year-on-year revenue growth to INR 15,600 million for Q2FY27.
- Profit after tax increased 39% to INR 1,818 million during the same period.
- North America market accounted for 72% of revenue; Europe increased share to 16%.
- Finished dosages represented 73% of sales, with API, PFI, and peptides CDMO contributing to the balance.
Financial performance
- EBITDA for Q2FY27 stood at INR 3,376 million, maintaining a margin of 22%.
- Profit before tax for the quarter was INR 2,434 million, up 38% year-on-year.
- Net cash position improved markedly from a net debt position of INR 1,012 million in Q1FY27 to INR 8,280 million at quarter-end.
Regulatory and governance context
- The company recently completed a US FDA audit at its Gagillapur facility.
- Observations from the audit are expected to be addressed fully through corrective actions without operational impact.
Strategic context
- Granules India filed three potential first-to-file ANDAs in the first half of FY27, signaling a shift towards complex generics and peptides CDMO.
- Strong cash position supports planned investments in research and development, manufacturing capabilities, and quality improvements.
Highlights
- Q2FY27 revenue at INR 15,600 million, up 20% year-on-year
- Profit after tax rose 39% to INR 1,818 million
- EBITDA margin maintained at 22% for Q2FY27
- North America accounted for 72% of revenue; Europe increased to 16%
- Net cash position improved to INR 8,280 million from net debt of INR 1,012 million in Q1FY27
- Company filed three potential first-to-file ANDAs in the first half of FY27
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Source Information
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Bagmane Prime Office REIT Declares ₹5,270 Million Distribution and Reports ₹3,997.99 Million Profit for Q2 FY 2026-27
Bagmane Prime Office REIT declared a total distribution of ₹5,270 million or ₹1.55 per unit for the quarter ended September 30, 2026, comprising ₹1,122 million as interest and ₹4,148 million as dividend. The REIT also reported a profit of ₹3,997.99 million during this period and declared its net asset value at ₹113.61 per unit.
Read Full Story
TBO Tek Limited Reports 53% Revenue Growth and ₹152 Crore Adjusted EBITDA in Q2 FY27
TBO Tek Limited announced its Q2 FY27 consolidated financial results with revenue rising 53% year-on-year to ₹866 crore and adjusted EBITDA increasing 47% to ₹152 crore, supported by broad-based growth across India, APAC, Europe, North America, and a notable recovery in its Middle East business.
Read Full Story
Amara Raja Energy & Mobility Reports ₹250.71 Crore Profit Before Tax and 13% Revenue Growth in Q2 FY27
Amara Raja Energy & Mobility Limited reported a profit before tax of ₹250.71 crore and a 13% increase in revenue to ₹3,843.25 crore for the quarter ending September 30, 2026 (Q2 FY27), also announcing an interim dividend of ₹4.30 per equity share.
Read Full Story
